Biogen Inc. (VIE:BIIB)
Austria · Delayed Price · Currency is EUR | Market Cap | 22.54B +18.5% |
| Revenue (ttm) | 8.42B +2.2% |
| Net Income | 1.10B -20.8% |
| EPS | 7.49 -21.4% |
| Shares Out | n/a |
| PE Ratio | 20.47 |
| Forward PE | 11.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 11 |
| Open | 157.95 |
| Previous Close | 157.55 |
| Day's Range | 154.65 - 158.00 |
| 52-Week Range | 98.96 - 170.00 |
| Beta | n/a |
| RSI | 42.75 |
| Earnings Date | Apr 30, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Why This Pharma Stock More Than Doubled Today
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
• Biogen stock is moving in positive territory. Why is BIIB stock advancing?
US FDA approves higher-dose of Biogen's genetic disorder drug
The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, offering patients a potentiall...
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patien...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people livin...
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) ...
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taki...
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy ...
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Fr...
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings
Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.
Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.
Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.
Biogen forecasts annual profit above estimates as Leqembi sales pick up
Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs battle pressure from ch...
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating the high-dose regimen o...
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifi...
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy
Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare diseases, state of the biotech sector, and more.